206 related articles for article (PubMed ID: 24158473)
1. Severe hypocalcemia after denosumab in a patient with acquired Fanconi syndrome.
Shafqat H; Alquadan KF; Olszewski AJ
Osteoporos Int; 2014 Mar; 25(3):1187-90. PubMed ID: 24158473
[TBL] [Abstract][Full Text] [Related]
2. Severe hypophosphatemia induced by denosumab in a patient with osteomalacia and tenofovir disoproxil fumarate-related acquired Fanconi syndrome.
Chung TL; Chen NC; Chen CL
Osteoporos Int; 2019 Feb; 30(2):519-523. PubMed ID: 30171299
[TBL] [Abstract][Full Text] [Related]
3. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
[TBL] [Abstract][Full Text] [Related]
4. Denosumab improves clinical manifestations of hypophosphatemic osteomalacia by adefovir-induced Fanconi syndrome: a case report.
Kunii T; Iijima T; Jojima T; Shimizu M; Kase M; Sakurai S; Kogai T; Usui I; Aso Y
J Med Case Rep; 2019 Apr; 13(1):99. PubMed ID: 31003599
[TBL] [Abstract][Full Text] [Related]
5. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
[TBL] [Abstract][Full Text] [Related]
6. Identification of the risk factors associated with hypocalcemia induced by denosumab.
Okada N; Kawazoe K; Teraoka K; Kujime T; Abe M; Shinohara Y; Minakuchi K
Biol Pharm Bull; 2013; 36(10):1622-6. PubMed ID: 23934346
[TBL] [Abstract][Full Text] [Related]
7. Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency.
Watkins KR; Rogers JE; Atkinson B
Support Care Cancer; 2015 Jun; 23(6):1657-62. PubMed ID: 25421444
[TBL] [Abstract][Full Text] [Related]
8. Denosumab-Associated Severe Hypocalcemia in a Patient With Chronic Kidney Disease.
Salim SA; Nair LR; Thomas L; Garla V; Palabindala V; Agarwal M; Fülöp T
Am J Med Sci; 2018 May; 355(5):506-509. PubMed ID: 29753381
[TBL] [Abstract][Full Text] [Related]
9. [Inhibition of RANK ligand to treat bone metastases].
Body JJ
Bull Cancer; 2013 Nov; 100(11):1207-13. PubMed ID: 24158618
[TBL] [Abstract][Full Text] [Related]
10. Denosumab-induced hypocalcemia in a patient with hyperthyroidism: a case report.
Park SY; Kim J; Chung HY
Osteoporos Int; 2022 Jan; 33(1):305-308. PubMed ID: 34232341
[TBL] [Abstract][Full Text] [Related]
11. High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis.
Ishikawa K; Nagai T; Tsuchiya K; Oshita Y; Kuroda T; Ito H; Tani S; Dodo Y; Toyone T; Inagaki K
Clin Interv Aging; 2018; 13():1929-1934. PubMed ID: 30349211
[TBL] [Abstract][Full Text] [Related]
12. [Symptomatic hypocalcaemia on denosumab use].
Baptista Lopes V; Robbrecht D; van Thiel S; van Guldener C
Ned Tijdschr Geneeskd; 2013; 157(29):A6159. PubMed ID: 23859106
[TBL] [Abstract][Full Text] [Related]
13. Severe hypocalcemia following denosumab injection in a hemodialysis patient.
McCormick BB; Davis J; Burns KD
Am J Kidney Dis; 2012 Oct; 60(4):626-8. PubMed ID: 22854051
[TBL] [Abstract][Full Text] [Related]
14. The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases.
Lechner B; DeAngelis C; Jamal N; Emmenegger U; Pulenzas N; Giotis A; Sheehan P; Tsao M; Bedard G; Chow E
Support Care Cancer; 2014 Jul; 22(7):1765-71. PubMed ID: 24515277
[TBL] [Abstract][Full Text] [Related]
15. New anti-resorptives and antibody mediated anti-resorptive therapy.
Farrier AJ; Sanchez Franco LC; Shoaib A; Gulati V; Johnson N; Uzoigwe CE; Choudhury MZ
Bone Joint J; 2016 Feb; 98-B(2):160-5. PubMed ID: 26850419
[TBL] [Abstract][Full Text] [Related]
16. The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.
Capozzi A; Lello S; Pontecorvi A
Gynecol Endocrinol; 2014 Jun; 30(6):403-8. PubMed ID: 24592987
[TBL] [Abstract][Full Text] [Related]
17. Severe and prolonged hypocalcemia after a single dose of denosumab for metastatic breast cancer with diffuse bone involvement without prior calcium/vitamin D supplementations.
Uhm SJ; Hall JA; Herrington JD
J Oncol Pharm Pract; 2021 Jul; 27(5):1287-1290. PubMed ID: 33081580
[TBL] [Abstract][Full Text] [Related]
18. Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency.
Ungprasert P; Cheungpasitporn W; Srivali N; Kittanamongkolchai W; Bischof EF
Am J Emerg Med; 2013 Apr; 31(4):756.e1-2. PubMed ID: 23399342
[TBL] [Abstract][Full Text] [Related]
19. Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation.
Saito Y; Takekuma Y; Komatsu Y; Sugawara M
Biol Pharm Bull; 2021; 44(12):1819-1823. PubMed ID: 34853264
[TBL] [Abstract][Full Text] [Related]
20. Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy.
Iizumi S; Shimoi T; Nishikawa T; Kitano A; Sasada S; Shimomura A; Noguchi E; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
Intern Med; 2017 Nov; 56(21):2879-2882. PubMed ID: 28943574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
